Status:
TERMINATED
Iron Deficiency and Hereditary Haemorrhagic Telangiectasia
Lead Sponsor:
Imperial College London
Conditions:
Hereditary Haemorrhagic Telangiectasia
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Managing iron deficiency is important for more than 1 billion individuals worldwide, to avoid blood transfusions, or excessive strain on vital organs that depend on iron-containing haemoglobin to deli...
Detailed Description
Relevant patients due to come to clinic or the programmed investigation unit will be offered the opportunity to participate in the study. Up to 100 consenting individuals will * have an additional 1...
Eligibility Criteria
Inclusion
- Hereditary haemorrhagic telangiectasia (HHT). Definite diagnosis of HHT by international criteria.
- No iron tablets or treatment taken on day of assessment
- Ability to provide informed consent.
Exclusion
- Inability to provide informed consent
- Intercurrent infection or illness predicted to modify iron absorption.
- Needle phobia.
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT01908543
Start Date
July 1 2013
End Date
July 1 2015
Last Update
September 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wellcome Trust-McMichael Clinical Research Facility, Imperial college London London, United Kingdom W12 0NN
London, United Kingdom, W12 0NN